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Abstract
Background We investigated the association between body mass index (BMI) and breast cancer risk in women at increased 
risk of breast cancer receiving tamoxifen or anastrozole compared with placebo using data from the International Breast 
Cancer Intervention Studies [IBIS-I (tamoxifen) and IBIS-II (anastrozole)].
Methods Baseline BMI was calculated from nurse assessed height and weight measurements for premenopausal (n = 3138) 
and postmenopausal (n = 3731) women in IBIS-I and postmenopausal women in IBIS-II (n = 3787). The primary endpoint 
was any breast cancer event (invasive and ductal carcinoma in situ). We used Cox proportional hazards regression to calculate 
hazard ratios (HRs) for risk after adjustment for covariates.
Results There were 582 (IBIS-I) and 248 (IBIS-II) breast cancer events [median follow-up = 16.2 years (IQR 14.4–17.7) 
and 10.9 years (IQR 8.8–13.0), respectively]. In adjusted analysis, women with a higher BMI had an increased breast can-
cer risk in both IBIS-I [HR = 1.06 per 5 kg/m2 (0.99–1.15), p = 0.114] and in IBIS-II [HR per 5 kg/m2 = 1.21 (1.09–1.35), 
p < 0.001]. In IBIS-I, the association between BMI and breast cancer risk was positive in postmenopausal women [adjusted 
HR per 5 kg/m2 = 1.14 (1.03–1.26), p = 0.01] but not premenopausal women [adjusted HR per 5 kg/m2 = 0.97 (0.86–1.09), 
p = 0.628]. There was no interaction between BMI and treatment group for breast cancer risk in either IBIS-I (p = 0.62) or 
IBIS-II (p = 0.55).
Conclusions Higher BMI is associated with greater breast cancer risk in postmenopausal women at increased risk of the 
disease, but no effect was observed in premenopausal women. The lack of interaction between BMI and treatment group on 
breast cancer risk suggests women are likely to experience benefit from preventive therapy regardless of their BMI.
Trial registration Both trials were registered [IBIS-I: ISRCTN91879928 on 24/02/2006, retrospectively registered (http://
www.isrct n.com/ISRCT N9187 9928); IBIS-II: ISRCTN31488319 on 07/01/2005, retrospectively registered (http://www.
isrct n.com/ISRCT N3148 8319)]
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Introduction
Breast cancer is the most common cancer in women world-
wide and is the leading cause of cancer-related death [1]. 
Women with first- and second-degree relatives with breast 
cancer are at increased risk, particularly if multiple rela-
tives are affected at a younger age [2]. Excess adiposity 
and weight gain are associated with an increased risk of 
breast cancer developing after the menopause but appear to 
reduce the risk of developing premenopausal breast cancer 
[3–6], particularly among those aged under 35 years [7, 8]. 
The association between weight and breast cancer risk is 
Samuel G. Smith and Ivana Sestak are Joint first authors.
Previous presentation: A version of this manuscript was presented 
as a poster at the American Society of Clinical Oncology Annual 
Meeting (2018).
 * Samuel G. Smith 
 s.smith1@leeds.ac.uk
Extended author information available on the last page of the article
 Breast Cancer Research and Treatment
1 3
generally stronger for oestrogen-receptor-positive (ER+) 
breast cancers [9–11], although there is evidence for an 
association with ER-tumours [12].
Most evidence on the association between weight and 
breast cancer risk is from studies of women at general popu-
lation risk, with adjustment for family history [6]. Observa-
tional data suggest that the relationship between BMI and 
breast cancer risk may be similar among women with and 
without a family history of the disease [13, 14]. However, 
data from the National Surgical Adjuvant Breast and Bowel 
Project (NSABP)-P1 preventive therapy trial are not consist-
ent with this observation [15]. Among women assessed as 
having a 5-year breast cancer risk of at least 1.66%, higher 
BMI was associated with an increased risk of premenopausal 
breast cancer but not postmenopausal breast cancer. Addi-
tional evidence examining the relationship between weight 
and breast cancer risk in women at increased risk is needed 
to clarify this issue.
In the NSABP-P1 and P2 trials, the interaction between 
BMI and treatment group on breast cancer risk was exam-
ined [15]. Women in the P1 trial were randomised to receive 
either tamoxifen or placebo [16], and participants in the P-2 
trial were randomised to receive either tamoxifen or ralox-
ifene [17]. Analysis of both trials demonstrated no inter-
action between treatment group and BMI on breast cancer 
risk for either premenopausal or postmenopausal women. 
Similar observations have been made in the adjuvant setting 
with women using tamoxifen to prevent recurrence [18, 19]. 
However, higher BMI has been found to reduce the effi-
cacy of aromatase inhibitors (AIs) such as anastrozole and 
letrozole in the adjuvant setting [20–24]. No data have been 
reported investigating the interaction between BMI and AIs 
on breast cancer risk in the primary prevention setting.
We used data from two large preventive therapy trials 
evaluating tamoxifen vs. placebo (International Breast can-
cer Intervention Study (IBIS-I) [25] and anastrozole vs. 
placebo (IBIS-II) [26] to estimate the relationship between 




Data were from the IBIS-I and II trials, and patient char-
acteristics and eligibility criteria have been reported pre-
viously [25–27]. Briefly, between April 1992 and March 
2001. women in IBIS-I were recruited from centres in the 
UK, Australia, New Zealand and Europe if they were aged 
35–70 years and had an increased breast cancer risk. Meno-
pausal status was recorded at study entry, with postmenopau-
sal defined if they had 12 consecutive months of amenorrhea 
or had an oophorectomy. Eligibility criteria were designed 
so that women had a relative risk of at least ten times higher 
than the general population if they were 35–39 years of age, 
four times higher if they were 40–44 years of age and two 
times higher if they were 45–70 years of age. In general 
terms, increased risk was determined from family history, 
previous lobular carcinoma in situ or atypical hyperplasia, 
by the Tyrer-Cuzick risk assessment tool [28].
IBIS-II participants were recruited between February 
2003 and January 2012 and were included if they were 
postmenopausal, 40–70 years of age, and at increased risk 
of breast cancer due to their family history or a personal his-
tory of abnormal benign breast disease (atypical hyperplasia 
or lobular carcinoma in situ). Eligibility criteria in IBIS-II 
meant that women had a relative risk of breast cancer that 
was at least two times higher than the general population if 
they were aged 45–60 years of age, 1.5 times higher if they 
were aged 60–70 years, and four times higher if they were 
aged 40–44 years of age. Women not meeting the aforemen-
tioned eligibility criteria were eligible if they had a 10-year 
breast cancer risk of at least 5% as assessed by the Tyrer-
Cuzick risk assessment tool [28]. Specific eligibility criteria 
for both trials are reported in the study protocol (Online 
Appendix).
IBIS-I participants were randomly assigned to 5 years 
of treatment with tamoxifen (20 mg) or matching placebo. 
The same approach was taken in the IBIS-II prevention 
trial comparing anastrozole (1 mg) with matching placebo. 
Women were actively followed for at least 5 years in both 
trials. In IBIS-I, women were followed up in the clinic or 
by telephone at 6-month intervals. In IBIS-II, women were 
followed up in the clinic at baseline, 6 and 12 months, and 
then annually until the 5-year endpoint. In addition to clini-
cal visits, cancer events and deaths were reported to the trial 
office via national registries and postal questionnaires, and 
this has continued following completion of active treatment. 
All participants from both trials are being followed up on a 
regular basis unless they have died or withdrew their consent 
for long-term follow-up. Sites were contacted by the trial 
office for further information on each breast cancer. Women 
who had not developed breast cancer after a minimum of 
10 years’ follow-up in IBIS-I were invited to enrol into the 
IBIS-II trial. Local ethics committees for each participating 
site approved the IBIS-I trial, and the UK North West Mul-
ticentre Research Ethics Committee approved the IBIS-II 
trial. Both trials were done in accordance with the Declara-
tion of Helsinki, under the principles of good clinical prac-
tice. Both trials were registered (IBIS-I: ISRCTN91879928; 
IBIS-II: ISRCTN31488319).
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Body mass index
In both trials, height (cm) and weight (kg) were measured 
by clinical staff at baseline, although there was no stand-
ard protocol for this process. BMI was calculated using 
these data, and women were classified as underweight 
or healthy weight (BMI < 24.9 kg/m2), overweight (BMI 
between 25.0 and 29.9 kg/m2) or obese (BMI ≥ 30.0 kg/
m2). For continuous BMI, hazard ratios are presented for 
a 5 kg/m2 change.
Statistical analysis
All analyses were completed on women for whom base-
line BMI was available. The primary outcome was any 
breast cancer (invasive and ductal carcinoma in situ), and 
time to occurrence was defined as time from randomisa-
tion to diagnosis of breast cancer. Hazard ratios (HR) 
per 5-unit increase in BMI and corresponding 95% con-
fidence intervals (CIs) were estimated by the proportional 
hazards regression model, both with and without adjust-
ment for key covariates including age, hormone replace-
ment therapy (HRT) use, current or previous history of 
smoking and baseline menopausal status (for IBIS-I only). 
In IBIS-I, we adjusted for current or previous use of HRT, 
whereas in IBIS-II, it was previous HRT use only. Addi-
tional covariates were also considered including age at 
menarche, age at menopause, oophorectomy and the 
Tyrer-Cuzick risk score [28]. However, there were no sig-
nificant interactions between these factors and BMI on 
breast cancer risk, and therefore, they were not included 
in the models (data not shown). We also investigated 
interactions between treatment group and BMI on breast 
cancer risk. These analyses were based on likelihood ratio 
tests for an added interaction term. Time-to-occurrence 
curves were produced using the Kaplan–Meier method. 
All P values are two sided. Statistical significance was set 
at p = 0.05. Calculations were performed using STATA 
(version 13.1; Stata Corp, College Station, TX).
Results
Baseline BMI data were available for 6903 women in IBIS-I 
(3.5%, n = 251 missing) and 3750 women in IBIS-II (2.9%, 
n = 114 missing) (Fig. 1). There were 582 (IBIS-I) and 248 
(IBIS-II) breast cancer events with a median follow-up of 
16.2 years (IQR 14.4–17.7) and 10.9 years (IQR 8.8–13.0), 
respectively. Mean (SD) baseline BMI was 26.9 kg/m2 (5.2) 
in IBIS-I and 28.3 kg/m2 (5.4) in IBIS-II. In IBIS-I mean 
(SD) BMI was 26.8 kg/m2 (5.4) among premenopausal 
women and 27.1 kg/m2 (5.1) in postmenopausal women. 
Menopausal status was missing for 34 women in IBIS-I. 
Approximately one fifth (17%) of IBIS-I participants who 
had not developed breast cancer after 10 years of follow-
up chose to enrol into the IBIS-II trial. Characteristics for 
IBIS-I and IBIS-II participants by baseline BMI category 
are shown in Table 1.
In unadjusted analyses, baseline BMI was associated with 
a significant increased risk of breast cancer among the IBIS-
I cohort [HR = 1.07 per 5 kg/m2 (1.00–1.16), p = 0.049] and 
a significant increased risk in the IBIS-II cohort [HR = 1.21 
per 5 kg/m2 (1.09–1.34), p < 0.001]. These estimates were 
similar after adjustment, although the association in IBIS-I 
no longer reached statistical significance [IBIS-I: HR = 1.06 
per 5 kg/m2 (0.99–1.15), p = 0.114; IBIS-II: HR per 5 kg/
m2 = 1.20 (1.09–1.35), p < 0.001].
When BMI categories were used, breast cancer risk was 
increased among postmenopausal women with overweight 
and obesity compared with healthy weight women in both 
IBIS-I and IBIS-II cohorts (Table 2, Figs. 2b, 3). However, a 
statistically significant effect was only observed in the IBIS-
II trial among women with obesity at baseline compared to 
those with healthy weight [adjusted HR = 1.51 (1.10–2.08), 
p = 0.01] (Fig. 3). These effect estimates were marginally 
strengthened after exclusion of ER-negative tumours, but 
a heterogeneity test was not significant (data not shown).
The extent to which associations between BMI and breast 
cancer risk differed by menopausal status was investigated 
in the IBIS-I cohort. There was no association between 
BMI and breast cancer risk among premenopausal women 
[adjusted HR = 0.97 per 5 kg/m2 (0.86–1.09), p = 0.628], 
Fig. 1  CONSORT flow dia-
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but a significant increase in risk was observed with higher 
BMI among postmenopausal women [adjusted HR = 1.14 
per 5  kg/m2 (1.03–1.26), p = 0.01]. A test for interac-
tion between BMI and menopausal status was significant 
(p = 0.038). Premenopausal women with obesity had a non-
significant decreased risk of breast cancer compared with 
healthy weight women (Fig. 2a). Postmenopausal women 
affected by overweight and obesity had an increased risk of 
breast cancer compared with healthy weight women; how-
ever, only the effect estimate for obesity reached statistical 
significance (Fig. 2b, Table 2).
In both IBIS-I and IBIS-II, the interaction between treat-
ment group and BMI (per 5 kg/m2) on breast cancer risk was 
not statistically significant (Table 3). In IBIS-I, the associa-
tion between BMI and breast cancer risk was similar among 
women in the tamoxifen and placebo groups. In IBIS-II, 
the association between BMI and breast cancer risk was 
marginally stronger in women in the placebo group com-
pared with the anastrozole group.
Discussion
In this analysis of two large randomised preventive therapy 
trials, among women at increased risk of breast cancer BMI 
was positively associated with breast cancer risk among 
postmenopausal women. Effect estimates were consistent 
with this observation when BMI was categorised. These 
observations support the scientific consensus that higher 
BMI increases postmenopausal breast cancer risk [3, 4, 6, 
29, 30]. To further examine the role of weight in breast can-
cer risk among higher risk populations, behavioural weight 
loss interventions should be examined within randomised 
Table 1  Baseline characteristics by body mass index group (kg/m2) in the IBIS-I and IBIS-II prevention trials
BMI kg/m2, IQR interquartile range, HRT hormone replacement therapy
a In IBIS-I, HRT was either current or previous use, whereas in IBIS-II, it was previous HRT use only
b Missing IBIS-I: N = 221; IBIS-II N = 73
IBIS-I (tamoxifen vs. placebo) (N = 6903) IBIS-II (anastrozole vs. placebo) (N = 3750)
BMI < 25
(N = 2878, 41.7%)
BMI: 25–29.9
(N = 2391, 34.6%)
BMI > 30
(N = 1634, 23.7%)
BMI < 25
(N = 1140, 30.4%)
BMI: 25–29.9
(N = 1420, 37.9%)
BMI > 30
(N = 1190, 31.7%)
Randomised to preven-
tive therapy (%)
50.3 49.0 50.7 50.2 48.9 50.1
HRT  usea (%) 26.4 26.7 24.0 46.3 48.4 46.7
Current/history of 
smoking (%)
20.7 18.2 14.5 14.9 9.9 8.9
Postmenopausal (%) 50.5 57.9 54.9 100 100 100
10-year Tyrer-Cuzick % 
risk, median (IQR)b
5.5 (4.4–7.0) 5.8 (4.7–7.5) 6.0 (4.7–7.7) 7.0 (5.3–9.2) 8.0 (6.1–10.2) 8.0 (6.0–10.5)
Age (years), median 
(IQR)
49 (45–53) 50 (46–56) 49 (45–53) 59 (54–63) 60 (56–64) 60 (55–63)
Table 2  Relationship between 
baseline BMI and incidence 
of breast cancer among IBIS-I 
and IBIS-II postmenopausal 
participants
Hazard ratios for continuous estimates are per 5 unit increase in baseline BMI
a IBIS-II analyses adjusted for IBIS-I participation
b Adjusted for age, HRT use, current or previous history of smoking, IBIS-I participation (IBIS-II analyses 
only) and menopausal status (IBIS-I analyses only)
BMI (kg/m2) IBIS-I (N = 3731) IBIS-II (N = 3750)
N Events (%) HR (95% CI) N Events (%) HR (95% CI)
Unadjusted Continuous 1.15 (1.04–1.27) 1.21 (1.09–1.34)a
< 25.0 1463 113 (7.7%) Ref 1140 64 (5.6) Ref
25.0–29.9 1371 131 (9.6%) 1.26 (0.98–1.62) 1420 87 (6.1) 1.12 (0.81–1.54)
≥ 30 896 90 (10.0%) 1.34 (1.01–1.76) 1190 97 (8.1) 1.51 (1.10–2.07)
Adjustedb Continuous 1.14 (1.03–1.26) 1.20 (1.09–1.35)
< 25.0 Ref Ref
25.0–29.9 1.23 (0.95–1.58) 1.11 (0.80–1.54)
≥ 30 1.30 (0.98–1.71) 1.51 (1.10–2.08)
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trials with breast cancer endpoints. However, sample sizes 
may be prohibitive [31].
We did not observe a protective effect of BMI on breast 
cancer risk among premenopausal women, although there 
was a possible small protective effect among premenopausal 
women with obesity. Reports of a protective effect of weight 
have been observed in younger premenopausal women at 
population level risk [7, 8, 32], and observational cohorts 
of women with a family history of breast cancer [33]. The 
effects of BMI on breast cancer risk by menopausal group 
were different when comparing the IBIS-I and NSABP trials 
[15]. A number of factors could explain this. No hetero-
geneity between BMI and menopausal status was reported 
in the NSABP-P1 trial, and hence, their result might have 
been a chance finding. Eligibility criteria for the trials were 
different, and therefore, the populations under study may 
not be directly comparable. For example, women in IBIS-I 
were at lower risk than P1 trial participants; in both IBIS 
896 855 811 545 34>30
1371 1325 1257 878 4825-29.9
1463 1405 1362 1011 62<25
Number at risk
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  a: Premenopausal
BMI Events (%) HR (95% CI)
<25 116 (8.2%) Reference
25-25.9 80 (8.1%) 1.00 (0.76-1.34)
>30 50 (6.9%) 0.85 (0.61-1.19)
Fig. 2  Kaplan–Meier graph for BMI categories and breast cancer in a premenopausal women and b postmenopausal women the IBIS-I trial
Fig. 3  Kaplan–Meier graph 
for BMI categories and breast 
cancer postmenopausal women 
in the IBIS-II trial
BMI Events (%) HR (95% CI)
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trials, participants were less likely to have obesity and previ-
ous HRT usage was higher in the NSABP-P1 trial. Meno-
pausal status was only assessed at baseline for the IBIS-I 
and NSABP-P1 trials, and therefore, different proportions 
of women may have become postmenopausal during trial 
follow-up. Despite the larger sample size available for the 
NSABP analysis, median follow-up was longer in both IBIS-
I and IBIS-II cohorts, likely resulting in higher statistical 
power.
In the adjuvant setting, there is evidence that overweight 
and obesity may reduce the efficacy of anastrozole [20–23], 
but not tamoxifen [18, 19]. Our data are among the first 
to investigate this topic in the primary prevention setting. 
We did not find convincing evidence to suggest women 
with higher BMIs experience differential benefit of preven-
tive therapy. Women are likely to experience benefit from 
tamoxifen and anastrozole preventive therapy regardless of 
their BMI. These data also indicate that preventive therapy 
is unlikely to completely mitigate the excess breast cancer 
risk among postmenopausal women with a higher BMI. A 
complementary approach of weight management and pre-
ventive therapy may optimally reduce breast cancer risk in 
this population.
Effect sizes for the relationship between BMI and breast 
cancer risk were slightly but non-significantly larger when 
ER-negative tumours were removed. The larger effect 
between BMI and ER-positive breast cancer is supported 
by NSABP-P1 and P2 data [15], as well as many studies 
including mainly women with a general population risk [6, 
9–11]. While data were available on tumour characteristics 
including size, grade and nodal status, sample sizes were 
too small to conduct meaningful sub-group analysis. Future 
research using larger cohorts is needed to investigate the 
relationship between BMI and breast tumour subtypes [7, 
9, 11, 12].
This study benefited from a large set of well-character-
ised samples. The length of follow-up and linkage with 
national registry data provided a unique opportunity to 
investigate the relationship between BMI and breast cancer 
risk in a higher risk cohort. There were also limitations. 
We used BMI as a weight assessment, calculated from 
baseline measured height and weight, thereby reducing 
the reporting bias observed in many studies that use self-
report. However, no standard protocol was employed for 
weight measurement. Alternative anthropometric measures 
such as waist or body fat measures may be more informa-
tive for investigating associations with breast cancer risk, 
particularly for younger women [34–36]. Our observed 
effects reflect associations with baseline BMI and baseline 
menopausal status (IBIS-I), and therefore, do not account 
for postmenopausal transition, adult weight gain or weight 
in early adulthood, which may be important factors in 
breast cancer risk [37]. They may also have been affected 
by detection bias, whereby lumps in women with over-
weight or obesity are more difficult to palpate than women 
with healthy weight. This could result in a delayed diag-
nosis, therefore, increasing postmenopausal breast can-
cer incidence. However, national screening data indicate 
that mammography screening is more sensitive in heavier 
women [38]. Women with a higher BMI are at greater 
risk of thromboembolic events [39] and, therefore, may 
have had to cease tamoxifen treatment more frequently. 
These women would therefore be expected to have a higher 
risk of breast cancer as they have experienced less benefit 
from preventive therapy. However, the lack of relationship 
between weight and preventive therapy adherence suggests 
that this is unlikely to be a major factor [40, 41]. Our 
analysis was on an intention-to-treat basis, and therefore, 
the small differences in medication adherence between the 
treatment and control groups may have affected our effect 
estimates [42, 43]. Weight gain has been observed among 
women using preventive therapy; however, a previous 
report using the IBIS cohorts indicated that this generally 
occurred in the first 12 months of participation and was 
similar among treatment and placebo arms [44].
In summary, higher baseline BMI was associated with 
an increased risk of breast cancer in postmenopausal 
women in two separate trials of women at increased risk of 
the disease. Among the premenopausal women in IBIS-I, 
there was no relationship between BMI and breast cancer 
risk. Women are likely to experience benefit from tamox-
ifen and anastrozole preventive therapy regardless of their 
BMI. Women at increased risk of breast cancer should be 
encouraged to achieve and maintain a healthy weight irre-
spective of their decision to initiate or decline preventive 
therapy. Supportive weight control programmes alongside 
chemoprevention may be required to achieve maximal risk 
reduction.
Supplementary Information The online version contains supplemen-
tary material available at https ://doi.org/10.1007/s1054 9-021-06141 -7.
Table 3  Relationship between baseline BMI and incidence of any 
breast cancer according to treatment received and trial
Analyses adjusted for age, HRT, current or previous history of smok-
ing, IBIS-I participation (IBIS-II analyses only) and menopausal sta-
tus (IBIS-I analyses only)
Hazard ratios for continuous estimates are per 5 unit increase in base-
line BMI
IBIS-I IBIS-II
HR (95% CI) HR (95% CI)
Placebo 1.01 (0.99–1.03) 1.23 (1.09–1.38)
Tamoxifen 1.02 (0. 99–1.04)
Anastrozole 1.14 (0.93–1.39)
P-interaction 0.62 0.55
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